SpaceX reportedly could file for an IPO this week. These funds allow you to invest right now

SpaceX is reportedly preparing to file an IPO prospectus as soon as this week and could raise more than $75 billion, with a likely Nasdaq listing and aim for early entry into the Nasdaq-100. Several funds have concentrated exposure: Baron Partners (BPTRX) holds ~a third of its portfolio in SpaceX (with Tesla taking total Musk-related exposure to >50%); BPTRX retail shares are down ~5% YTD 2026 but were +24% in 2025. Baron Focused Growth (BFGIX) holds nearly 25% in SpaceX (Tesla ~6%) and its institutional shares are down >4% YTD; ARK Venture (ARKVX) holds ~18% in SpaceX and is +6% YTD after +55% in 2025. The Private-Public Crossover ETF (XOVR) has ~45% exposure to SpaceX (next largest holding Nvidia ~4%) and is down ~15% YTD after +12% in 2025.

Analysis

A very large private-to-public conversion will act like a temporary supply shock to equity market intermediation: dealers will need balance-sheet capacity to underwrite, hedge, and absorb new floating supply, which should widen primary-market spreads and increase executed fees for the listing venue. That fee capture is front-loaded (days–weeks around pricing) while the market-impact of incremental float works through over months as passive indexes, ETFs and rebalancing algorithms incorporate the new market-cap weight.

Crossover vehicles and concentrated active funds face a two-way liquidity squeeze: they may buy the IPO to capture immediate uplifts but will also face redemption pressure and mark-to-market hits if the IPO prices below private marks. Expect NAV reratings in the short run of +/-10–30% for funds with material pre‑IPO private allocations as lockup expiries and aftermarket performance provide new price discovery.

Key catalysts to watch are the S‑1 disclosures (esp. revenue breakdowns and governance provisions), book‑building velocity on pricing days, and index provider inclusion calendars — each has distinct timing: filing → days; pricing → 1–2 weeks; index reconstitution and lockups → 1–12 months. Tail risks that would reverse a bullish fee/flow case include weak demand at pricing, aggressive insider selling, or regulatory interventions that limit retail access, any of which would rapidly shift dealers from buyers to sellers.

From a positioning perspective, this is an event that favors liquidity/fee-earning platforms and penalizes levered crossover/hyper-concentrated funds; the efficient trade is to capture fee-flow upside while hedging valuation repricing of private-rich ETFs and concentrated active managers.

Key Decisions for Investors

• Long NDAQ (beta play on listing/fee capture): Buy NDAQ 3-month ATM call options sized to risk no more than 1% of position capital. Rationale: captures underwriting/listing fee upside and increased market-structure revenues in the 0–3 month window. Target 2x return if implied volatility falls post-pricing; stop at 50% premium loss.
• Pair trade — long NDAQ / short private-to-public ETF (short XOVR or equivalent): Size 60/40 long/short to isolate exchange fee capture vs private-valuation rerating. Timeframe: 1–6 months. Risk/reward: asymmetry from concentrated fee gains up-front vs gradual NAV downside if private marks reprice downward.
• Hedge concentrated-Musk/insider exposure (TSLA hedge): Buy TSLA 3‑month put spread (sell a further OTM put) to cap cost while protecting against a 15–30% downside should liquidity flows force correlated selling across related names. Use as insurance for concentrated long exposures in funds/portfolios.
• Short concentrated crossover/venture ETFs on weak entry (if IPO prices materially below private marks): Initiate a small short or buy put options in the 1–6 month window to play forced redemptions and NAV compression. Risk: if aftermarket prints rich, losses can be rapid—limit sizing and use option structures to cap downside.
• Long NVDA (convex tech exposure): Add a small tactical overweight to NVDA (3–6 month horizon) as a relative winner if passive reweighting and index flows favor existing large-cap tech incumbents over new-issue volatility. Trim into any >20% rally; protect with a trailing stop or short call against sizable position gains.